Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401:1039–1052

Article  CAS  PubMed  Google Scholar 

Song C, Lv J, Liu Y, Chen JG, Ge Z, Zhu J, et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw Open. 2019;2:e195718

Article  PubMed  PubMed Central  Google Scholar 

Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16:1399–1408

Article  PubMed  Google Scholar 

CollaboratorS PO. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2022;8:879–907

Google Scholar 

Chen S, Mao W, Guo L, Zhang J, Tang S. Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China. BMJ Glob Health. 2020;5:e002306

Article  PubMed  PubMed Central  Google Scholar 

Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Zhonghua Gan Zang Bing Za Zhi. 2022;30:1309–1331

Google Scholar 

EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370–398

Google Scholar 

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283

Article  PubMed  Google Scholar 

Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:463–472

Article  CAS  PubMed  Google Scholar 

Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4:227–238

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Huang A, Zhao Y. Spontaneous loss of chronic HBV infection markers in treatment-naïve children: a systematic review and pooled meta-analyses. Expert Rev Anti Infect Ther. 2021;19:649–660

Article  CAS  PubMed  Google Scholar 

Hsu YC, Yeh ML, Wong GL, Chen CH, Peng CY, Buti M, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J Infect Dis. 2021;224:1890–1899

Article  CAS  PubMed  Google Scholar 

Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, et al. Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive HBsAg carriers: a meta-analysis. Front Immunol. 2021;12:7793472021

Article  Google Scholar 

Wu D, Yan W, Tan DT, Peng SB, Chen Y, Jiang J, et al. Combination of NA, PEG-IFN alpha-2b and GM-CSF enhanced hbsab production in NA experienced CHB patients (the anchor a study): an interim analysis. J Hepatol. 2020;73:S860

Article  Google Scholar 

Mo Z, Xie D, Fu L, Zhang W, Wei J, Li G, et al. Functional cure based on pegylated interferon ɑ-2b therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China)-4 years data update. Hepatology. 2022;76:S24–S25

Google Scholar 

Chen XY, Ren S, Lu JF, Ma LN, Zheng SJ, Hu ZJ. Combination therapy in HBeAg-negative chronic hepatitis B patients with low-level viremia to nucleos (tide) analogues. J Hepatol. 2022;77:S844–S844

Article  Google Scholar 

Liu Y, Li H, Yan X, Wei J. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B. J Viral Hepat. 2019;26(Suppl 1):69–76

Article  CAS  PubMed  Google Scholar 

Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, et al. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat. 2019;26(Suppl 1):77–84

Article  CAS  PubMed  Google Scholar 

Han GR, Zhou GL, Chen C, Wang CX. Efficacy of pegylated interferon alpha-2b therapy in nucleos(t)ide analogue-treated HBV postpartum women: an exploratory study. Hepatology. 2021;74:527A

Google Scholar 

Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of pegylated interferon plus tenofovir combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e antigen -positive chronic hepatitis B: a real-world experience. Clin Ther. 2021;43:572–581.e573

Article  CAS  PubMed  Google Scholar 

Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14:958–972

Article  PubMed  Google Scholar 

Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferonα-2a. Virol Sin. 2021;36:311–320

Article  PubMed  Google Scholar 

Li M, Xie S, Bi X, Sun F, Zeng Z, Deng W, et al. An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients. Front Microbiol. 2022;13:9605892022

Google Scholar 

Wu Y, Liu Y, Lu J, Cao Z, Jin Y, Ma L, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance. Clin Gastroenterol Hepatol. 2020;18:514–516.e512

Article  PubMed  Google Scholar 

Song A, Wang X, Lu J, Jin Y, Ma L, Hu Z, et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2021;28:601–612

Article  PubMed  PubMed Central  Google Scholar 

Ren P, Li H, Huang Y, Jiang J, Guo S, Cao Z, et al. A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. Antiviral Res. 2021;194:105163

Article  CAS  PubMed  Google Scholar 

Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial). J Hepatol. 2014;61:777–784

Article  CAS  PubMed  Google Scholar 

Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, et al. HBsAg Loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol. 2018;6:25–34

Article  PubMed  PubMed Central  Google Scholar 

Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen <= 1500 IU/mL: an observational study. World J Gastroenterol. 2020;26:1525–1539

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bao XL, Guo J, Xiong F, Qu YC, Gao Y, Gu N, et al. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs. Int J Infect Dis. 2020;96:562–566

Article  CAS  PubMed  Google Scholar 

Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon alfa-2a: week 120 analysis. Dig Dis Sci. 2018;63:3487–3497

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66:1058–1066

Article  CAS  PubMed  Google Scholar 

Erken R, Loukachov V, van Dort K, van den Hurk A, Takkenberg RB, de Niet A, et al. Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B. Hepatology. 2022;76:196–206

Article  CAS  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928

Article  PubMed  PubMed Central  Google Scholar 

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses; 2018

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–716

Article  PubMed  Google Scholar 

Yoo S, Kim JY, Lim YS, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol. 2022;77:939–946

Article  PubMed  Google Scholar 

Zhang S, Wang C, Lu B. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Reg Health West Pac. 2023;2023:1007380

Google Scholar 

Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, et al. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med. 2021;9:1365

Article